AnalystsInsight

Cecilia Romero (Barclays): Analyst Track Record and Price‑Target Accuracy

How often Cecilia Romero’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 6 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Cecilia Romero ranks #636 of 1,000 analysts in Exent’s scoring (4.7★).
  • 100.0% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 307 days; 100.0% of calls were up 12 months later.
  • Most‑covered stocks: BME-SAN, BME-BBVA, BME-CABK, BME-UNI.
  • Free on Exent: Cecilia Romero’s full record, with ratings 3 days after publication.

Cecilia Romero’s track record at a glance

Cecilia Romero of Barclays ranks #636 of the 1,000 analysts Exent scores, with a 4.7★ rating and a focus on financials. Over a 7‑year lookback, 100.0% of Cecilia’s price targets were reached, 47.6 points above the 52.4% average across all analysts.

MetricCecilia RomeroAll analysts
Price‑target hit rate100.0%52.4%
Median days to hit target307 days91 days
Calls up after 12 months100.0%64.0%
Median 12‑month return of calls+51.5%+13.4%
Hit rate, last 2 years——
Average worst drop after a call−9.4%—
Ratings in the sample6—
Stocks covered9—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetCecilia Romero
Under 30 days0.0%
30–90 days0.0%
90–180 days0.0%
Over 180 days100.0%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Cecilia Romero covers most

StockRatings in the sample
BME-SAN89
BME-BBVA76
BME-CABK67
BME-UNI50
BME-BKT50
BME-SAB43
LON-0RJN21
SAN2

In the past year Cecilia’s ratings were 48% Buy, 45% Hold and 7% Sell.

Cecilia Romero’s latest ratings

DateStockActionRatingPrice target
Jul 31, 2026BME-UNIReiterated: SellSell$3.20
Jul 30, 2026BME-BBVAReiterated: HoldHold$24.10
Jul 30, 2026BME-CABKReiterated: BuyBuy$13.70
Jul 23, 2026BME-BKTReiterated: HoldHold$16.70
Jul 23, 2026BME-SANReiterated: BuyBuy$14.00
Jul 20, 2026BME-BBVAReiterated: HoldHold$23.60
Jul 14, 2026BME-BBVARated: HoldHold$23.60
Jul 14, 2026BME-SANRated: BuyBuy$13.70
Jul 14, 2026BME-BKTRated: HoldHold$16.10
Jul 14, 2026BME-UNIDowngraded: SellSell$3.10
Jul 14, 2026BME-CABKRated: BuyBuy$13.80
Jul 1, 2026LON-0RJNReiterated: BuyBuy$1.11
  • Jul 31, 2026
    Stock
    BME-UNI
    Action
    Reiterated: Sell
    Rating
    Sell
    Price target
    $3.20
  • Jul 30, 2026
    Stock
    BME-BBVA
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $24.10
  • Jul 30, 2026
    Stock
    BME-CABK
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $13.70
  • Jul 23, 2026
    Stock
    BME-BKT
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $16.70
  • Jul 23, 2026
    Stock
    BME-SAN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $14.00
  • Jul 20, 2026
    Stock
    BME-BBVA
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $23.60
  • Jul 14, 2026
    Stock
    BME-BBVA
    Action
    Rated: Hold
    Rating
    Hold
    Price target
    $23.60
  • Jul 14, 2026
    Stock
    BME-SAN
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $13.70
  • Jul 14, 2026
    Stock
    BME-BKT
    Action
    Rated: Hold
    Rating
    Hold
    Price target
    $16.10
  • Jul 14, 2026
    Stock
    BME-UNI
    Action
    Downgraded: Sell
    Rating
    Sell
    Price target
    $3.10
  • Jul 14, 2026
    Stock
    BME-CABK
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $13.80
  • Jul 1, 2026
    Stock
    LON-0RJN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $1.11

Cecilia’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Cecilia Romero’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Cecilia Romero ranks #636 of 1,000 with a 4.7★ rating. 100.0% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 100.0% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Cecilia Romero’s success rate is 79.4% by the ranking source and 100.0% by Exent’s price-target hit-rate backtest, with a median of 307 days to reach a target.

Cecilia Romero (Barclays) covers 9 stocks, mostly in financials. The most frequently rated are BME-SAN, BME-BBVA, BME-CABK, BME-UNI, BME-BKT.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.